Prucalopride for minimizing bowel ileus following ERCP with CO2 insufflation: A prospective randomize double-blinded placebo controlled trial
Phase 3
- Conditions
- Must have provided written informed consent prior to any screening procedures.Male/female patients between 18 to 65 years of age at the time of informed consent who visit the clinic for having ERCP procedure.ERCP
- Registration Number
- TCTR20210814001
- Lead Sponsor
- Srinagarind Hospital Khonkaen University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Enrolling by invitation
- Sex
- All
- Target Recruitment
- 194
Inclusion Criteria
Must have provided written informed consent prior to any screening procedures.
Male/female patient between 18 to 65 years of age at the time of informed consent who visit the clinic for having ERCP procedure.
Exclusion Criteria
Suspected Intestinal obstruction or gastrointestinal leakage.
Contradicted to anesthetic agents.
Uncontrolled concomitant conditions; heart failure, hepatic failure, kidney failure, diabetes, hyperthyroidism or hypothyroidism.
Taking antiplatelets at least 7 days prior to enrollment
Taking warfarin at least 3 days prior to the enrollment
Pregnant women
Previous major surgery of gastrointestinal tract
Allergy to Prucalopride
Platelet normal
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Proportion of bowel ileus 90 min Film
- Secondary Outcome Measures
Name Time Method Abdominal girt 30, 60 and 90 min Lenght